"AstraZeneca will invest in two existing sites at Cambridge and Macclesfield, completing the construction of the Rosalind Franklin building and building a lab of the future that will use digital and data tools to advance drug development."
"Keir Starmer announced the investment in the House of Commons, stating that this move would protect jobs and represents a significant new investment in UK life sciences."
"Pascal Soriot, the company's chief executive, thanked the government for their effort to improve access for patients, including four new drug approvals since the beginning of the year."
AstraZeneca announced a £300 million investment in the UK, focusing on its Cambridge and Macclesfield sites. This decision follows a period of disillusionment with the UK business environment, particularly regarding NHS drug pricing and medicine availability. The investment includes completing the Rosalind Franklin building in Cambridge and establishing a 'lab of the future' in Macclesfield. Keir Starmer emphasized the importance of this investment for job protection, while AstraZeneca's CEO acknowledged government efforts to enhance patient access to new drugs.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]